DUBLIN--(BUSINESS WIRE)--Oct 29, 2018--The "Rosacea - Epidemiology Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

The total prevalent population of Rosacea was found to be 47,359,758, in the year 2016.

Rosacea - Epidemiology Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Rosacea in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Rosacea market report gives the thorough understanding of the Rosacea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Rosacea in the US, Europe, and Japan.

Rosacea Epidemiology

The Rosacea epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Gender specific prevalence, Diagnosed prevalent population, Sub-type specific diagnosed prevalence and Severity-Specific diagnosed prevalence] scenario of Rosacea in the 7MM.

Key Topics Covered:

1. Key Insights

2. Rosacea: Market Overview at a Glance

3. Disease Background and Overview: Rosacea

4. Epidemiology and Patient Population

5. 7MM Total Prevalent Patient Population of Rosacea

6. 7MM Total Diagnosed Prevalent Patient Population of Rosacea

7. Country Wise-Epidemiology of Rosacea Disease

8. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/3bwgmd/global—rosacea?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181029005326/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Dermatological Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/29/2018 06:18 AM/DISC: 10/29/2018 06:18 AM


Copyright Business Wire 2018.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for Reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.